These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 18220748)
41. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Westerfeld N; Pluschke G; Zurbriggen R Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241 [TBL] [Abstract][Full Text] [Related]
42. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry. Krell T; Manin C; Nicolaï MC; Pierre-Justin C; Bérard Y; Brass O; Gérentes L; Leung-Tack P; Chevalier M Biotechnol Appl Biochem; 2005 Jun; 41(Pt 3):241-6. PubMed ID: 15377284 [TBL] [Abstract][Full Text] [Related]
43. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Liu H; Tu Z; Feng F; Shi H; Chen K; Xu X Acta Pharm; 2015 Jun; 65(2):105-16. PubMed ID: 26011928 [TBL] [Abstract][Full Text] [Related]
44. Influenza virosomes as vaccine adjuvant and carrier system. Moser C; Müller M; Kaeser MD; Weydemann U; Amacker M Expert Rev Vaccines; 2013 Jul; 12(7):779-91. PubMed ID: 23885823 [TBL] [Abstract][Full Text] [Related]
46. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436 [TBL] [Abstract][Full Text] [Related]
47. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665 [TBL] [Abstract][Full Text] [Related]
48. The effect of endosomal escape peptides on in vitro gene delivery of polyethylene glycol-based vehicles. Moore NM; Sheppard CL; Barbour TR; Sakiyama-Elbert SE J Gene Med; 2008 Oct; 10(10):1134-49. PubMed ID: 18642401 [TBL] [Abstract][Full Text] [Related]
49. Virosome: An engineered virus for vaccine delivery. Ali H; Akbar M; Iqbal B; Ali F; Sharma NK; Kumar N; Najmi A; Albratty M; Alhazmi HA; Madkhali OA; Zoghebi K; Alam MS Saudi Pharm J; 2023 May; 31(5):752-764. PubMed ID: 37181145 [No Abstract] [Full Text] [Related]
50. Influenza virosomes as a vaccine adjuvant and carrier system. Moser C; Amacker M; Zurbriggen R Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642 [TBL] [Abstract][Full Text] [Related]
55. Endosome Escape Strategies for Improving the Efficacy of Oligonucleotide Delivery Systems. Wan Y; Moyle PM; Toth I Curr Med Chem; 2015; 22(29):3326-46. PubMed ID: 26303176 [TBL] [Abstract][Full Text] [Related]
56. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296 [TBL] [Abstract][Full Text] [Related]
57. Enhanced immune responses induced by vaccine using Sendai virosomes as carrier. Li Q; Gao JQ; Qiu LY; Cui FD; Jin Y Int J Pharm; 2007 Feb; 329(1-2):117-21. PubMed ID: 17046184 [TBL] [Abstract][Full Text] [Related]